ECO ANIMAL HEALTH GROUP PLC

Share Issue/Capital Change • Jun 6, 2023

National Storage Mechanism | Additional information

RNS Number : 6885B

Eco Animal Health Group PLC

06 June 2023

6 June 2023

ECO Animal Health Group plc

("ECO" or the "Company")

Issue of Equity and Total Voting Rights

ECO Animal Health Group plc, a leader in the development, registration and marketing of pharmaceutical products for global animal health markets, confirms that a former employee has exercised options over 22,973 ordinary shares of 5 pence each ("Ordinary Shares") under the Company's Deferred Bonus Scheme.

Application has been made to the London Stock Exchange for 22,973 new Ordinary Shares to be admitted to trading on AIM. Admission and dealings in the new Ordinary Shares is expected to occur at 8.00 a.m. on 9 June 2023.

The new Ordinary Shares will rank pari passu with the existing Ordinary Shares.

Total Voting Rights

Following Admission, the Company's total issued share capital will consist of 67,744,889 Ordinary Shares with one voting right per share. The Company does not hold any Ordinary Shares in treasury. The total number of voting rights in the Company is therefore 67,744,889.

The above figure of 67,744,889 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure Guidance and Transparency Rules.

Enquiries

ECO Animal Health Group plc	0208 447 8899
David Hallas (CEO)
Chris Wilks (CFO)
IFC Advisory	0203 934 6630
Graham Herring / Zach Cohen
Singer Capital Markets (Nominated Adviser & Joint Broker)	0207 496 3051
Phil Davies / George Tzimas / Sam Butcher
Investec (Joint Broker)	0207 597 5970
Gary Clarence / Daniel Adams / Carlo Spingardi
Equity Development	0207 065 2692
Hannah Crowe / Matt Evans

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

IOEEADKSEDPDEFA